|
|
|
|
|
Received: 20 January 2024
|
|
|
|
|
|
| [1] |
Alsagaff M Y,Susilo H,Pramudia C,et al.Rapid atrial fibrillationin the emergency department[J].Heart Int,2022,16(1):12-19.
|
| [2] |
张树峰,张许梅,刘晶晶,等.不同血管活性药物在缺血性脑卒中合并房颤患者神经介入手术中的应用效果比较[J].武警医学,2023,34(8):660-667.
|
| [3] |
Long B,Brady W J,Gottlieb M.Emergency medicine updates:atrial fibrillationwith rapid ventricular response[J].Am J Emerg Med,2023,74(17):57-64.
|
| [4] |
Hoffer M,Tran Q K,Hodgson R,et al.Utility of magnesiumsulfate in the treatment of rapid atrial fibrillation in the emergencydepartment:a systematic review and meta-analysis[J].Eur J Emerg Med,2022,29(4):253-261.
|
| [5] |
Enayati A,Gin J H,Sajeev J K,et al.Efficacy of intravenous magnesium for the managementof non-post operative atrial fibrillation with rapid ventricular response:asystematic review and meta-analysis[J].J Cardiovasc Electrophysiol,2023,34(5):1286-1295.
|
| [6] |
Long B,Keim S M,Gottlieb M,et al.What is the best agent for ratecontrol of atrial fibrillation with rapid ventricular response?[J].J Emerg Med,2022,63(3):467-476.
|
| [7] |
McGuire D,Ahdi H,Mielke N,et al.Tamsulosin-induced atrial fibrillationwith rapid ventricular response[J].Cureus,2022,14(6):257-264.
|
| [8] |
Tchouapi P C,Anderson K E,Hein P N.Intravenous magnesium as an adjunct tostandard of care for treatment of atrial fibrillation with rapid ventricularresponse[J].Acad Emerg Med,2023,30(7):779-781.
|
| [9] |
Cicala E,Velicu A C,Gherghina A,et al.Dual Atrioventricular nodal non-reentrant tachycardia misdiagnosed as rapid atrial fibrillation-the role ofadenosine[J].Maedica(Bucur),2022,17(3):735-739.
|
| [10] |
Niforatos J D,Ehmann M R,Balhara K S,et al.Management of atrial flutter and atrial fibrillation with rapidventricular response in patients with acute decompensated heart failure:Asystematic review[J].Acad Emerg Med,2023,30(2):124-132.
|
| [11] |
Li Q,Fang Y,Peng D W,et al.Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improvingatrial remodeling in spontaneously hypertensive rats[J].Eur J Pharmacol,2023,95(2):175-179.
|
| [12] |
Ha S H,Jeong S,Park J Y,et al.Association between rapid ventricular response andstroke outcomes in atrial fibrillation-related cardiac embolic stroke[J].Cerebrovasc Dis,2024,53(1):69-78.
|
| [13] |
Nagy S Z,Kasi P,Afonso V X,et al.Cycle length evaluation in persistent atrial fibrillation usingkernel density estimation to identify transient and stable rapid atrialactivity[J].Cardiovasc Eng Technol,2022,13(2):219-233.
|
| [14] |
Siddiqui M N,Henley E,Xue B.Refractory atrial fibrillation with rapidventricular response as a heralding sign of propofol infusion syndrome in apatient with COVID-19[J].BMJ Case Rep,2023,16(5):252-263.
|
| [15] |
Bishop J J,Akram G.Diltiazem dosing strategies in the management ofatrial fibrillation with rapid ventricular rate[J].Cureus,2021,13(10):188-192.
|
| [16] |
Kovacs B,Yakupoglu H Y,Eriksson U,et al.Medical therapy withflecainide and propafenone in atrial fibrillation:Long-term clinical experiencein the tertiary care setting[J].Cardiol J,2023,30(1):82-90.
|
| [17] |
Chin C G,Hsieh Y C,Lin W S,et al.An open-label randomizednoninferior study of generic name and brand name of propafenone for rhythmcontrol in patients with paroxysmal atrial fibrillation[J].J Chin Med Assoc,2023,86(5):472-478.
|
| [18] |
Okin P M,Hille D A,Wachtell K,et al.On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensivepatients with left ventricular hypertrophy[J].Blood Press,2020,29(5):319-326.
|
| [19] |
Noel J E,Sinclair C F.Radiofrequency ablation for benign thyroid nodules[J].J Clin Endocrinol Metab,2023,109(1):12-17.
|
| [20] |
任伟豪,张艺舰,张誉籍,等.自主神经与心房纤颤关系研究[J].临床军医杂志,2020,46(6):642-646.
|
| [21] |
Zhang L,Po S S,Wang H,et al.Autonomic remodeling:how atrial fibrillation begets atrial fibrillation in thefirst 24 hours[J].J Cardiovasc Pharmacol,2015,66(3):307-315.
|
| [22] |
Qin M,Zeng C,Liu X.The cardiac autonomic nervous system:a target formodulation of atrial fibrillation[J].Clin Cardiol,2019,42(6):644-652.
|
| [23] |
Sinen O,Bülbül M.The role of autonomic pathways in peripheral apelin-induced gastrointestinal dysmotility:involvement of the circumventricularorgans[J].Exp Physiol,2021,106(2):475-485.
|
| [24] |
Mowaswes M,Biton Y,Belhassen B.Type 1 brugada-electrocardiogram:a rarepresentation in a 57-year-old woman with paroxysmal atrial fibrillation treatedwith a therapeutic dose of propafenone[J].Isr Med Assoc J,2021,23(7):456-458.
|
| [25] |
Karelas D,Papanikolaou J,Kossyvakis C,et al.Old stuff stilltrending:use of propafenone as a safety net until catheter ablation in apatient with documented pre-excited atrial fibrillation and wolff-parkinson-white syndrome-a classic case report[J].Eur Heart J,2021,5(12):4-8.
|
| [26] |
Huang R,Lin J,Gong K,et al.Comparison of amiodarone and propafenone in blanking period after radiofrequencycatheter ablation in patients with atrial fibrillation:a propensity score-matched study[J].Biomed Res Int,2020,26(18),2020:181-183.
|
| [27] |
Taha H S,Youssef G,Omar R M,et al.Efficacy and speed of conversion of recent onset atrial fibrillation using oralpropafenone versus parenteral amiodarone:a randomized controlled comparativestudy[J].Indian Heart J,2022,74(3):212-217.
|
| [28] |
Shoemaker M B,Yoneda Z T,Crawford D M,et al.A Mechanistic clinical trial using(r)-versus(s)-propafenone to test ryr2(ryanodine receptor)inhibition for the prevention of atrial fibrillation induction[J].Circ Arrhythm Electrophysiol,2022,15(10):713-718.
|
| [29] |
Boriani G,Capucci A,Lenzi T,et al.Propafenone forconversion of recent-onset atrial fibrillation.a controlled comparison betweenoral loading dose and intravenous administration[J].Chest,1995,108(2):355.
|
| [30] |
韩爱国,孟秋云.静脉推注普罗帕酮与毛花甙C治疗阵发性快速心房纤颤即时疗效与安全性的观察[J].健康大视野:医学分册,2005,13(11):7-8.
|
| [31] |
龙 琴,方 凯,李 庆,等.普罗帕酮与胺碘酮治疗室上性心律失常疗效及对血气指标和心肌损伤标志物的影响[J].昆明医科大学学报,2020,41(5):136-139.
|
| [32] |
滕丽峰,林 劲.普罗帕酮与胺碘酮在混合性心律失常治疗中的联合应用观察[J].山东医药,2021,61(27):83-85.
|
| [33] |
Giacobbo A,Soares E V,Bernardes A M,et al.Atenolol removalby nanofiltration: a case-specific mass transfer correlation[J].Water Sci Technol,2020,81(2):210-216.
|
| [34] |
吕旭晶.通脉养心丸联合阿替洛尔治疗心律失常的疗效观察[J].中国保健营养(下旬刊),2014,7(6):3484-3485.
|
| [35] |
罗 卉.达比加群酯联合阿替洛尔对老年持续性心房纤颤患者AngⅡ/Rac1/STAT3通路的影响[J].心血管康复医学杂志,2023,32(1):29-33.
|
| [36] |
项建立.胺碘酮联合阿替洛尔对心律失常患者心率变异性及血压水平的影响[J].现代诊断与治疗,2020,31(23):3738-3739.
|
| [37] |
杨飞飞,李卿慧.缬沙坦联合阿替洛尔治疗老年持续性心房纤颤的临床疗效及对IL-6、AngⅡ、血管内皮功能的影响[J].中西医结合心脑血管病杂志,2018,16(24):3686-3688.
|
|
|
2024, Vol. 35 
